Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
1:1 active treatment: placebo, blinded trial, evaluating the effect of a 4-week treatment
period with topical C-82 on skin expression of two gene biomarker surrogates (THBS1 and COMP)
for the modified Rodnan skin score (MRSS). Study subjects will be randomized to apply the
active study medication daily for 4 weeks to either the right or left forearm and placebo to
the contralateral forearm.